Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins
{"title":"非小细胞肺癌辅助化疗的真实结果和毒性:单中心研究。","authors":"Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins","doi":"10.2217/lmt-2022-0014","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.</p><p><strong>Results: </strong>62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.</p><p><strong>Conclusion: </strong>High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 1","pages":"LMT58"},"PeriodicalIF":0.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4b/lmt-12-58.PMC10241113.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.\",\"authors\":\"Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins\",\"doi\":\"10.2217/lmt-2022-0014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.</p><p><strong>Results: </strong>62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.</p><p><strong>Conclusion: </strong>High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.</p>\",\"PeriodicalId\":43551,\"journal\":{\"name\":\"Lung Cancer Management\",\"volume\":\"12 1\",\"pages\":\"LMT58\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4b/lmt-12-58.PMC10241113.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2022-0014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2022-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.
Aim: Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.
Methods: We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.
Results: 62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.
Conclusion: High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
